A Systematic and Critical Review of Bacteriophage Therapy Against Multidrug-resistant ESKAPE Organisms in Humans

Bacteriophages (phages) may constitute a natural, safe, and effective strategy to prevent and control multidrug-resistant organisms (MDROs), and ESKAPE (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter species) path...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Clinical infectious diseases 2019-06, Vol.69 (1), p.167-178
Hauptverfasser: El Haddad, Lynn, Harb, Cynthia P., Gebara, Marc A., Stibich, Mark A., Chemaly, Roy F.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 178
container_issue 1
container_start_page 167
container_title Clinical infectious diseases
container_volume 69
creator El Haddad, Lynn
Harb, Cynthia P.
Gebara, Marc A.
Stibich, Mark A.
Chemaly, Roy F.
description Bacteriophages (phages) may constitute a natural, safe, and effective strategy to prevent and control multidrug-resistant organisms (MDROs), and ESKAPE (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter species) pathogens in particular. Few clinical studies have assessed the safety and efficacy of phages in patients infected with MDROs. This systematic review summarizes and critically evaluates published studies of phages in clinical practice and presents the appropriate phage selection criteria, as well as recommendations for clinicians and scientists for a successful therapy. Articles were identified through a search of the PubMed, Ovid, EMBASE, and Cochrane Library databases. Among 1102 articles and abstracts, 30 studies were selected and evaluated using selective inclusion criteria, phage criteria, and study characteristics. Most studies showed efficacy (87%) and safety (67%) of the tested phages, but few studies examined phage resistance (35%). Clinical studies and regulatory changes are needed to determine the safety and efficacy of phages and to advance their use in patients with MDRO infections.
doi_str_mv 10.1093/cid/ciy947
format Article
fullrecord <record><control><sourceid>jstor_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_2130060634</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><jstor_id>26794913</jstor_id><oup_id>10.1093/cid/ciy947</oup_id><sourcerecordid>26794913</sourcerecordid><originalsourceid>FETCH-LOGICAL-c339t-9cd72d0d838027cae39006e8364b9b3d6a57dd518a1028000d8cbdc0f5b9f3043</originalsourceid><addsrcrecordid>eNp90MtLAzEQBvAgiu-LdyUXQYTVyWZfOdZSrVip2Hpeskm2RvZlklX63xvZ2qOHYebw42P4EDojcEOA0VuhpZ81i9IddEhimgZJzMiuvyHOgiij2QE6svYDgJAM4n10QIGymKTsEHUjvFhbp2rutMC8kXhstD95hV_Vl1bfuC3xHRdOGd1273yl8PJdGd6t8WjFdWMdfu4rp6XpV4FRVlvHG4cni6fRywTPzYo32tYW6wZP-5o39gTtlbyy6nSzj9Hb_WQ5ngaz-cPjeDQLBKXMBUzINJQg_fMQpoIrygASldEkKlhBZcLjVMqYZJxAmAF4KQopoIwLVlKI6DG6GnI70372yrq81laoquKNanubh4T6QEjoL70eqDCttUaVeWd0zc06J5D_Npz7hvOhYY8vNrl9USu5pX-VenA5gLbv_g86H9yHda3ZyjBJWcQIpT9o5Y4J</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2130060634</pqid></control><display><type>article</type><title>A Systematic and Critical Review of Bacteriophage Therapy Against Multidrug-resistant ESKAPE Organisms in Humans</title><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Oxford University Press Journals All Titles (1996-Current)</source><source>Alma/SFX Local Collection</source><creator>El Haddad, Lynn ; Harb, Cynthia P. ; Gebara, Marc A. ; Stibich, Mark A. ; Chemaly, Roy F.</creator><creatorcontrib>El Haddad, Lynn ; Harb, Cynthia P. ; Gebara, Marc A. ; Stibich, Mark A. ; Chemaly, Roy F.</creatorcontrib><description>Bacteriophages (phages) may constitute a natural, safe, and effective strategy to prevent and control multidrug-resistant organisms (MDROs), and ESKAPE (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter species) pathogens in particular. Few clinical studies have assessed the safety and efficacy of phages in patients infected with MDROs. This systematic review summarizes and critically evaluates published studies of phages in clinical practice and presents the appropriate phage selection criteria, as well as recommendations for clinicians and scientists for a successful therapy. Articles were identified through a search of the PubMed, Ovid, EMBASE, and Cochrane Library databases. Among 1102 articles and abstracts, 30 studies were selected and evaluated using selective inclusion criteria, phage criteria, and study characteristics. Most studies showed efficacy (87%) and safety (67%) of the tested phages, but few studies examined phage resistance (35%). Clinical studies and regulatory changes are needed to determine the safety and efficacy of phages and to advance their use in patients with MDRO infections.</description><identifier>ISSN: 1058-4838</identifier><identifier>EISSN: 1537-6591</identifier><identifier>DOI: 10.1093/cid/ciy947</identifier><identifier>PMID: 30395179</identifier><language>eng</language><publisher>US: Oxford University Press</publisher><subject>REVIEW ARTICLE</subject><ispartof>Clinical infectious diseases, 2019-06, Vol.69 (1), p.167-178</ispartof><rights>The Author(s) 2019</rights><rights>The Author(s) 2019. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com. 2019</rights><rights>The Author(s) 2019. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c339t-9cd72d0d838027cae39006e8364b9b3d6a57dd518a1028000d8cbdc0f5b9f3043</citedby><cites>FETCH-LOGICAL-c339t-9cd72d0d838027cae39006e8364b9b3d6a57dd518a1028000d8cbdc0f5b9f3043</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,777,781,1579,27905,27906</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30395179$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>El Haddad, Lynn</creatorcontrib><creatorcontrib>Harb, Cynthia P.</creatorcontrib><creatorcontrib>Gebara, Marc A.</creatorcontrib><creatorcontrib>Stibich, Mark A.</creatorcontrib><creatorcontrib>Chemaly, Roy F.</creatorcontrib><title>A Systematic and Critical Review of Bacteriophage Therapy Against Multidrug-resistant ESKAPE Organisms in Humans</title><title>Clinical infectious diseases</title><addtitle>Clin Infect Dis</addtitle><description>Bacteriophages (phages) may constitute a natural, safe, and effective strategy to prevent and control multidrug-resistant organisms (MDROs), and ESKAPE (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter species) pathogens in particular. Few clinical studies have assessed the safety and efficacy of phages in patients infected with MDROs. This systematic review summarizes and critically evaluates published studies of phages in clinical practice and presents the appropriate phage selection criteria, as well as recommendations for clinicians and scientists for a successful therapy. Articles were identified through a search of the PubMed, Ovid, EMBASE, and Cochrane Library databases. Among 1102 articles and abstracts, 30 studies were selected and evaluated using selective inclusion criteria, phage criteria, and study characteristics. Most studies showed efficacy (87%) and safety (67%) of the tested phages, but few studies examined phage resistance (35%). Clinical studies and regulatory changes are needed to determine the safety and efficacy of phages and to advance their use in patients with MDRO infections.</description><subject>REVIEW ARTICLE</subject><issn>1058-4838</issn><issn>1537-6591</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><recordid>eNp90MtLAzEQBvAgiu-LdyUXQYTVyWZfOdZSrVip2Hpeskm2RvZlklX63xvZ2qOHYebw42P4EDojcEOA0VuhpZ81i9IddEhimgZJzMiuvyHOgiij2QE6svYDgJAM4n10QIGymKTsEHUjvFhbp2rutMC8kXhstD95hV_Vl1bfuC3xHRdOGd1273yl8PJdGd6t8WjFdWMdfu4rp6XpV4FRVlvHG4cni6fRywTPzYo32tYW6wZP-5o39gTtlbyy6nSzj9Hb_WQ5ngaz-cPjeDQLBKXMBUzINJQg_fMQpoIrygASldEkKlhBZcLjVMqYZJxAmAF4KQopoIwLVlKI6DG6GnI70372yrq81laoquKNanubh4T6QEjoL70eqDCttUaVeWd0zc06J5D_Npz7hvOhYY8vNrl9USu5pX-VenA5gLbv_g86H9yHda3ZyjBJWcQIpT9o5Y4J</recordid><startdate>20190618</startdate><enddate>20190618</enddate><creator>El Haddad, Lynn</creator><creator>Harb, Cynthia P.</creator><creator>Gebara, Marc A.</creator><creator>Stibich, Mark A.</creator><creator>Chemaly, Roy F.</creator><general>Oxford University Press</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20190618</creationdate><title>A Systematic and Critical Review of Bacteriophage Therapy Against Multidrug-resistant ESKAPE Organisms in Humans</title><author>El Haddad, Lynn ; Harb, Cynthia P. ; Gebara, Marc A. ; Stibich, Mark A. ; Chemaly, Roy F.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c339t-9cd72d0d838027cae39006e8364b9b3d6a57dd518a1028000d8cbdc0f5b9f3043</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>REVIEW ARTICLE</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>El Haddad, Lynn</creatorcontrib><creatorcontrib>Harb, Cynthia P.</creatorcontrib><creatorcontrib>Gebara, Marc A.</creatorcontrib><creatorcontrib>Stibich, Mark A.</creatorcontrib><creatorcontrib>Chemaly, Roy F.</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical infectious diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>El Haddad, Lynn</au><au>Harb, Cynthia P.</au><au>Gebara, Marc A.</au><au>Stibich, Mark A.</au><au>Chemaly, Roy F.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A Systematic and Critical Review of Bacteriophage Therapy Against Multidrug-resistant ESKAPE Organisms in Humans</atitle><jtitle>Clinical infectious diseases</jtitle><addtitle>Clin Infect Dis</addtitle><date>2019-06-18</date><risdate>2019</risdate><volume>69</volume><issue>1</issue><spage>167</spage><epage>178</epage><pages>167-178</pages><issn>1058-4838</issn><eissn>1537-6591</eissn><abstract>Bacteriophages (phages) may constitute a natural, safe, and effective strategy to prevent and control multidrug-resistant organisms (MDROs), and ESKAPE (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter species) pathogens in particular. Few clinical studies have assessed the safety and efficacy of phages in patients infected with MDROs. This systematic review summarizes and critically evaluates published studies of phages in clinical practice and presents the appropriate phage selection criteria, as well as recommendations for clinicians and scientists for a successful therapy. Articles were identified through a search of the PubMed, Ovid, EMBASE, and Cochrane Library databases. Among 1102 articles and abstracts, 30 studies were selected and evaluated using selective inclusion criteria, phage criteria, and study characteristics. Most studies showed efficacy (87%) and safety (67%) of the tested phages, but few studies examined phage resistance (35%). Clinical studies and regulatory changes are needed to determine the safety and efficacy of phages and to advance their use in patients with MDRO infections.</abstract><cop>US</cop><pub>Oxford University Press</pub><pmid>30395179</pmid><doi>10.1093/cid/ciy947</doi><tpages>12</tpages></addata></record>
fulltext fulltext
identifier ISSN: 1058-4838
ispartof Clinical infectious diseases, 2019-06, Vol.69 (1), p.167-178
issn 1058-4838
1537-6591
language eng
recordid cdi_proquest_miscellaneous_2130060634
source Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Oxford University Press Journals All Titles (1996-Current); Alma/SFX Local Collection
subjects REVIEW ARTICLE
title A Systematic and Critical Review of Bacteriophage Therapy Against Multidrug-resistant ESKAPE Organisms in Humans
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-19T17%3A07%3A50IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-jstor_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20Systematic%20and%20Critical%20Review%20of%20Bacteriophage%20Therapy%20Against%20Multidrug-resistant%20ESKAPE%20Organisms%20in%20Humans&rft.jtitle=Clinical%20infectious%20diseases&rft.au=El%20Haddad,%20Lynn&rft.date=2019-06-18&rft.volume=69&rft.issue=1&rft.spage=167&rft.epage=178&rft.pages=167-178&rft.issn=1058-4838&rft.eissn=1537-6591&rft_id=info:doi/10.1093/cid/ciy947&rft_dat=%3Cjstor_proqu%3E26794913%3C/jstor_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2130060634&rft_id=info:pmid/30395179&rft_jstor_id=26794913&rft_oup_id=10.1093/cid/ciy947&rfr_iscdi=true